Skip to main content

Advertisement

SpringerLink
Log in

Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications

  • Review
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Michaelson MD, Smith MR (2005) Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23(32):8219–8224

    Article  PubMed  CAS  Google Scholar 

  2. Smith MR (2006) Markers of bone metabolism in prostate cancer. Cancer Treat Rev 1 (32 Suppl):23–26

    Article  Google Scholar 

  3. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164

    Article  PubMed  CAS  Google Scholar 

  4. Hussain SA, Weston R, Stephenson RN, George E, Parr NJ (2003) Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 92(7):690–694

    Article  PubMed  CAS  Google Scholar 

  5. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M et al (2000) Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164(4):1248–1253

    Article  PubMed  CAS  Google Scholar 

  6. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879–882

    Article  PubMed  CAS  Google Scholar 

  7. Fontana A, Delmas PD (2000) Markers of bone turnover in bone metastases. Cancer 88(12 Suppl):2952–2960

    Article  PubMed  CAS  Google Scholar 

  8. Suvanto-Luukkonen E, Risteli L, Sundstrom H, Penttinen J, Kauppila A, Risteli J (1997) Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy. Clin Chim Acta 266(2):105–116

    Article  PubMed  CAS  Google Scholar 

  9. Arai Y, Takeuchi H, Oishi K, Yoshida O (1992) Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate 20(3):169–177

    Article  PubMed  CAS  Google Scholar 

  10. Hanson DA, Eyre DR (1996) Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem 271(43):26508–26516

    Article  PubMed  CAS  Google Scholar 

  11. Demers LM, Costa L, Lipton A (2000) Biochemical markers and skeletal metastases. Cancer 88(12 Suppl):2919–2926

    Article  PubMed  CAS  Google Scholar 

  12. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR (1992) A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7(11):1251–1258

    Article  PubMed  CAS  Google Scholar 

  13. Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M (2001) Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19(1):45–51

    Article  PubMed  CAS  Google Scholar 

  14. Hofbauer LC, Neubauer A, Heufelder AE (2001) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92(3):460–470

    Article  PubMed  CAS  Google Scholar 

  15. Koga H, Naito S, Koto S, Sakamoto N, Nakashima M, Yamasaki T et al (1999) Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39(1):1–7

    Article  PubMed  CAS  Google Scholar 

  16. Koizumi M, Yonese J, Fukui I, Ogata E (2001) The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87(4):348–351

    Article  PubMed  CAS  Google Scholar 

  17. de la Piedra C, Castro-Errecaborde NA, Traba ML, Mendez-Davila C, Garcia-Moreno C, Rodriguez de Acuna L et al (2003) Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331(1–2):45–53

    Google Scholar 

  18. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P et al (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111(5):783–791

    Article  PubMed  CAS  Google Scholar 

  19. Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M (1996) Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol 156(5):1691–1695

    Article  PubMed  CAS  Google Scholar 

  20. Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL (1992) Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70(12):2870–2878

    Article  PubMed  CAS  Google Scholar 

  21. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11(4):607–615

    PubMed  CAS  Google Scholar 

  22. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K et al (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20(19):3972–3982

    Article  PubMed  Google Scholar 

  23. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA et al (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21(7):1232–1237

    Article  PubMed  Google Scholar 

  24. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97(1):59–69

    Article  PubMed  CAS  Google Scholar 

  25. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468

    PubMed  CAS  Google Scholar 

  26. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21(16):3150–3157

    Article  PubMed  CAS  Google Scholar 

  27. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ et al (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12(11 Pt 1):3361–3367

    Article  PubMed  CAS  Google Scholar 

  28. Lara PN Jr, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M et al (2006) A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 12(5):1556–1563

    Article  PubMed  CAS  Google Scholar 

  29. Lara PN, Longmate J, Stadler W, van Loan M, Wexler J, Quinn DI et al (2005) Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): results from a randomized California Cancer Consortium and Univ of Chicago trial. J Clin Oncol 23S(16S) Abst 4569

  30. Nelson JB (2005) Endothelin receptor antagonists. World J Urol 23(1):19–27

    Article  PubMed  CAS  Google Scholar 

  31. Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y et al (1997) Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer 80(9):1760–1767

    Article  PubMed  CAS  Google Scholar 

  32. Koizumi M, Yonese J, Fukui I, Ogata E (2002) Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol 167(4):1863–1866

    Article  PubMed  Google Scholar 

  33. Holen I, Shipman CM (2006) Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 110(3):279–291

    Article  CAS  Google Scholar 

  34. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC (2004) Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59(3):304–310

    Article  PubMed  CAS  Google Scholar 

  35. Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK et al (2006) Osteoprotegerin (OPG)—a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 118(8):1901–1908

    Article  PubMed  CAS  Google Scholar 

  36. Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M et al (1999) Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45(8 Pt 1):1240–1247

    PubMed  CAS  Google Scholar 

  37. Berruti A, Tucci M, Mosca A, Tarabuzzi R, Gorzegno G, Terrone C et al (2005) Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 93(6):633–638

    Article  PubMed  CAS  Google Scholar 

  38. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23(22):4925–4935

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

PNL is supported in part by RO1-CA120469, Veterans’ Administration of Northern California, and NIH NO1 CM17101.

Author information

Authors and Affiliations

  1. Department of Urology, University of California, Davis Medical Center, 4860 Y St, Suite 3500, Sacramento, CA, 95817, USA

    Eric C. Nelson & Christopher P. Evans

  2. Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, University of California, Davis, 4501 X Street, Sacramento, CA, 95817, USA

    Chong-Xian Pan & Primo N. Lara Jr

Authors
  1. Eric C. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher P. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chong-Xian Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Primo N. Lara Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Primo N. Lara Jr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nelson, E.C., Evans, C.P., Pan, CX. et al. Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. World J Urol 25, 393–399 (2007). https://doi.org/10.1007/s00345-007-0186-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-007-0186-3

Keywords

Search

Navigation